Dysregulation of Neutrophil-Endothelial Communication in Sepsis: Mechanisms and Therapeutic Perspectives.

Cells · 2026 · PMC13072018 · PMID 41972674

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Reparixin showed a trend toward limiting disease progression as an add-on therapy in COVID-19 severe pneumonia ( NCT04878055 ); the results of the ARDS clinical trial have not yet been reported ( NCT05496868 ) [ 190 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.